Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Morpholine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morpholine SCHEMBL28072685 | 1.00 | MEN1 (0.61) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL2808231 | 1.00 | MEN1 (0.61) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Sulfuric Acid SCHEMBL8024423 | 0.97 | KDM4E (0.67) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL15789446 | 0.97 | MEN1 (0.58) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL15789448 | 0.97 | MEN1 (0.58) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL15510575 | 0.90 | MEN1 (0.50) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL27791864 | 0.90 | MEN1 (0.50) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL10346420 | 0.89 | MEN1 (0.55) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL10346421 | 0.89 | MEN1 (0.55) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Morpholine SCHEMBL10346419 | 0.89 | MEN1 (0.55) | MEN1KMT2AKDM4EGAACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3822259-A1 | METHOD FOR SYNTHESIZING VALSARTAN | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2021-05-19 | — | — | EP | claimed |
| CN-112076110-A | Antibacterial cleaning solution for preventing and treating bedsores and preparation method thereof | 重庆返璞科技有限公司 | 2020-12-15 | — | — | CN | claimed |
| US-4298477-A | Regeneration of cation ion-exchange polishers | NALCO CHEMICAL COMPANY (US) | 1981-11-03 | — | — | US | claimed |
| EP-3166981-B1 | OLIGOSACCHARIDE COMPOSITIONS AND METHODS FOR PRODUCING THEREOF | DSM NUTRITIONAL PRODUCTS LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12514267-B2 | Oligosaccharide compositions for use as animal feed and methods of producing thereof | DSM NUTRITIONAL PRODUCTS, LLC (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250057202-A1 | OLIGOSACCHARIDE COMPOSITIONS FOR USE AS FOOD INGREDIENTS AND METHODS OF PRODUCING THEREOF | DSM NUTRITIONAL PRODUCTS LLC (US) | 2025-02-20 | — | — | US | disclosed |
| EP-3055453-B1 | LIGNOCELLULOSIC MATERIALS CONTAINING DEFIBRILLATED CELLULOSE | BASF SE (DE) | 2023-11-22 | — | — | EP | disclosed |
| US-20230339850-A1 | CANNABINOID SULFATE ESTERS, THEIR SALTS AND USES THEREOF | LONDON PHARMACEUTICALS AND RESEARCH CORPORATION (CA) | 2023-10-26 | — | — | US | disclosed |
| US-20230255240-A1 | OLIGOSACCHARIDE COMPOSITIONS FOR USE AS ANIMAL FEED AND METHODS OF PRODUCING THEREOF | MIDORI USA, INC. | 2023-08-17 | — | — | US | disclosed |
| CN-114395515-B | Lactobacillus harbini, microbial deodorant containing same and application of lactobacillus harbini and microbial deodorant | 青岛蔚蓝赛德生物科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| EP-4205553-A1 | OLIGOSACCHARIDE COMPOSITIONS FOR USE ANIMAL FEED AND METHODS OF PRODUCING THEREOF | DSM Nutritional Products, LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-1195981-A | Inverse Fluorocarbon Emulsion Compositions for Drug Delivery | ALLIANCE PHARMA (US) | 1998-10-14 | — | — | CN | disclosed |
| EP-0869120-A1 | Process for the preparation of nitroguanidine derivatives starting from 2-nitroimino-hexahydro-1,3,5-triazines in the presence of ammonia, primary or secondary amine | Mitsui Chemicals, Inc. (JP) | 1998-10-07 | — | — | EP | disclosed |
| US-5278293-A | Aromatic amide-alkylenesulfonic acid fiber-reactive dyes | BAYER AKTIENGESELLSCHAFT (DE) | 1994-01-11 | — | — | US | disclosed |
| US-5132410-A | Dyeing cellulose | BAYER AKTIENGESELLSCHAFT (DE) | 1992-07-21 | — | — | US | disclosed |
| US-4753736-A | USING AQUEOUS SOLUTION OF CITRATE SALT OF VOLATILE AMINE | BETZ LABORATORIES, INC. (US) | 1988-06-28 | — | — | US | disclosed |
| US-4417023-A | POLYOXYETHYLENE-OXYPROPYLENE-SILOXANE COPOLYMER | DIAMOND SHAMROCK CORPORATION (US) | 1983-11-22 | — | — | US | disclosed |
| EP-0009227-B1 | FLUORINATION PROCESS AND FLUORO ANALOGS OF HYDROCODONE AND OXYCODONE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-09-01 | — | — | EP | disclosed |
| US-4298477-A | Regeneration of cation ion-exchange polishers | NALCO CHEMICAL COMPANY (US) | 1981-11-03 | — | — | US | disclosed |
| US-3962150-A | NONIONIC SURFACTANT, ALCOHOL SOLVENT | RICHARDSON-MERRELL INC. (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255240-A1 | OLIGOSACCHARIDE COMPOSITIONS FOR USE AS ANIMAL FEED AND METHODS OF PRODUCING THEREOF | FUT5, FUT6, OSTC | MEN1 3453/4885KMT2A 4205/4885KDM4E 3999/4885 |
| US-20230339850-A1 | CANNABINOID SULFATE ESTERS, THEIR SALTS AND USES THEREOF | CNR2, CNR1, GPR18 | MEN1 2893/4885KMT2A 3852/4885KDM4E 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.